This article was first published on HWUpgrade.com.
Three months ago Transmeta launched its first ever
high-profile lawsuit against Intel Corporation. At that time, Transmeta
had recently made the transition from a company that offers low-power
chips to one that that licenses patents and performs R&D. With
licensing as its primary source of income, it was only natural for
Transmeta to file a lawsuit sooner or later.
Transmeta filed its lawsuit against Intel alleging that
Intel’s entire x86 microprocessor line, all the way back to the Pentium
Pro to its present day offerings, infringed on one or more of eleven
total patents held by Transmeta. Transmeta went on to say that Intel
had made over $100 billion on the processors pertaining to its patents
and requested the court for treble damages -- meaning that if Transmeta wins
it will be awarded triple the cost of the actual damages -- attorney's
fees and a licensing deal.
Intel finally responded to the lawsuit late last week by
countersuing Transmeta. The countersuit alleges that Transmeta has
breached seven patents held by Intel, many of which deal with methods
to control and reduce power consumption. Intel accuses Transmeta of
breaching its following patents: 5,745,375; 5,617,554; 5,802,605;
5,819,101; 5,881,275; 6,385,634; 6,418,529.
The countersuit centers on
Transmeta’s Crusoe, Efficeon and Efficeon 2 brands.
Intel's counter-suit was submitted to the same court Transmeta filed against Intel in three months ago, the U.S. District Court of Delaware. In addition to the the lawsuit, Intel presented a total of eleven defenses against Transmeta’s lawsuit:
- Non-infringement
- Invalidity
- Obviousness type double patenting
- Prosecution history estoppel
- The doctrine of laches
- License [sic]
- Equitable estoppel
- Ownership
- Marking
- Inequitable conduct and infectious unenforceability
- The doctrine of unclean hands
"As expected, Intel has filed a timely response," stated Greg Rose, Transmeta's director of corporate marketing. The company has not issued any further statement about the suit.